Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 129Carcinoma, Renal Cell 36Parkinson Disease 4, Autosomal Dominant Lewy Body 31Neoplasms 27Cholangiocarcinoma 23Endometrial Neoplasms 19Liver Neoplasms 16Melanoma 15Thyroid Neoplasms 13Stomach Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Biliary Tract Neoplasms 12Neoplasm Metastasis 9Squamous Cell Carcinoma of Head and Neck 8Recurrence 8Ovarian Neoplasms 8Breast Neoplasms 8Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 5Thyroid Carcinoma, Anaplastic 5Small Cell Lung Carcinoma 5Neuroendocrine Tumors 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Pancreatic Neoplasms 4Kidney Neoplasms 4Carcinoma, Transitional Cell 4Adenocarcinoma 4Thyroid Cancer, Papillary 3Solid Tumors 3

Interventions

elemene 2lenvatinib 1camrelizumab 1apatinib 1Oxaliplatin 1Folfox protocol 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Primary Liver Cancer × lenvatinib × Clear all
NCT05411757 2022-06-09

IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer

Shandong Public Health Clinical Center

Phase EARLY_PHASE1 Unknown
12 enrolled

Advanced Primary Liver Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡